Here's What Key Metrics Tell Us About Teleflex (TFX) Q1 Earnings

For the quarter ended March 2025, Teleflex (TFX) reported revenue of $700.67 million, down 5% over the same period last year. EPS came in at $2.91, compared to $3.21 in the year-ago quarter.The reported revenue represents a surprise of +0.22% over the Zacks Consensus Estimate of $699.13 million. With the consensus EPS estimate being $2.88, the EPS surprise was +1.04%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.Here is how Teleflex performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Geographic Revenues- Americas: $475.70 million versus $418.41 million estimated by eight analysts on average. Compared to the year-ago quarter, this number represents a +17.1% change. Geographic Revenues- Asia: $73.80 million compared to the $77.13 million average estimate based on eight analysts. Geographic Revenues- EMEA: $151.20 million versus $154.16 million estimated by eight analysts on average. Net Revenues- Interventional: $137.50 million versus $137.85 million estimated by 12 analysts on average. Compared to the year-ago quarter, this number represents a +2.1% change. Net Revenues- Interventional Urology: $71 million versus the 12-analyst average estimate of $69.11 million. The reported number represents a year-over-year change of -10.9%. Revenues- OEM (Original Equipment Manufacturer and Development Services): $63.90 million versus the 12-analyst average estimate of $70.27 million. The reported number represents a year-over-year change of -27.1%. Net Revenues- Vascular Access: $182.40 million versus $178.12 million estimated by 12 analysts on average. Compared to the year-ago quarter, this number represents a +0.6% change. Net Revenues- Anesthesia: $86.60 million compared to the $92.40 million average estimate based on 12 analysts. The reported number represents a change of -10.2% year over year. Net Revenues- Other: $53.50 million compared to the $49.30 million average estimate based on 12 analysts. The reported number represents a change of +2.1% year over year. Net Revenues- Surgical: $105.80 million compared to the $102.08 million average estimate based on 12 analysts. The reported number represents a change of +0.3% year over year. View all Key Company Metrics for Teleflex here>>>Shares of Teleflex have returned -3.1% over the past month versus the Zacks S&P 500 composite's -0.7% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.Zacks' Research Chief Names "Stock Most Likely to Double"Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.This top pick is among the most innovative financial firms. With a fast-growing customer base (already 50+ million) and a diverse set of cutting edge solutions, this stock is poised for big gains. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Teleflex Incorporated (TFX): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks